Progress in the application of intraoperative autologous blood transfusion in liver tumor surgery
10.13303/j.cjbt.issn.1004-549x.2025.09.022
- VernacularTitle:术中回收式自身输血在肝脏肿瘤手术中的应用进展
- Author:
Wenlong LI
1
;
Baohua QIAN
1
;
Haihui GU
1
Author Information
1. The First Affiliated Hospital of the Naval Medical University, Shanghai 200433, China
- Publication Type:Journal Article
- Keywords:
intraoperative autologous blood transfusion;
liver tumor;
allogeneic blood transfusion;
circulating tumor cells;
leukocyte depletion filter;
radiation irradiation;
microfluidics;
nanobiotechnology;
tumor immunotherapy;
patient blood management (PBM)
- From:
Chinese Journal of Blood Transfusion
2025;38(9):1259-1266
- CountryChina
- Language:Chinese
-
Abstract:
In liver tumor surgery, owing to the characteristics such as the abundant blood supply of the liver and the abnormal hyperplasia of tumor blood vessels, the risk of intraoperative hemorrhage is significantly elevated. Frequently, it is necessary to rely on allogeneic blood transfusion to maintain hemodynamic stability. It is well established that allogeneic blood transfusion poses risks such as immunosuppression and transmission of infectious agents, which may compromise postoperative recovery and long-term patient outcomes. Intraoperative autologous blood transfusion (IOABT) serves as a crucial strategy for blood conservation. The use of allogeneic blood can be effectively reduced by recovering, washing, and centrifuging blood from the patient's surgical field before transfusion to the patient. This article provides an overview of the application and research advancements in IOABT technology within the context of liver tumor surgery. It outlines the evolution of blood salvage techniques, core operational principles, and strategies to mitigate tumor cell dissemination, including the use of leukocyte filters and irradiation. Furthermore, it examines the clinical efficacy and safety of IOABT in both liver resection and liver transplantation, with particular attention to the potential risk of tumor cell reinfusion. Current evidence does not indicate an increased risk of tumor recurrence associated with this technique. Looking ahead, the integration of emerging technologies such as artificial intelligence, nanobiotechnology, and immunotherapy holds promise for further enhancing IOABT, ultimately enabling safer and more precise perioperative blood management strategies for patients undergoing liver tumor surgery.
